Treatment of common respiratory infections: The antibiotic dilemma by Naidoo, KT & Wilson, D
Respiratory tract infections are one of the commonest reasons for
a visit to a family physician, and given time constraints and per-
ceived patient expectations many consultations will end with an
antibiotic prescription. Antibiotic resistance among the respirato-
ry tract pathogens is clinically significant and increasing rapidly,
and clinicians treating outpatients with respiratory tract infections
need to grapple with the issue of whether or not an antibiotic
should be prescribed (Fig. 1). A recent study from the United
States1 gives insight into the manner in which clinicians respond
to these issues. The study reviewed the treatment of more than
24 000 adults presenting with nonspecific respiratory tract infec-
tions and revealed that 63% received a prescription for an oral
antibiotic. Importantly, the study excluded patients with chronic
bronchitis, asthma or chronic obstructive pulmonary disease
(COPD), and concluded that interventions are needed to reduce
antibiotic prescribing to limit the progression of antibiotic resist-
ance. 
How should clinicians responsibly approach the management of
viral upper respiratory tract infections (URTIs), sinusitis and bron-
chitis? Guidelines were developed in the 1980s and 1990s, but
were difficult to use in individual cases and did not take into
account varying antibiotic resistance in different regions. An
alternative approach is to consider each case on merit and,
when an antibiotic is necessary, to prescribe effectively.
The following three clinical scenarios will be discussed: 
• acute bronchitis
• acute sinusitis
• infective exacerbation of chronic bronchitis, COPD or
bronchiectasis.
ACUTE BRONCHITIS
Acute bronchitis is often preceded by a viral URTI. Symptoms
progress to include general malaise, retrosternal pain, dry ‘tickly’
cough and sputum production that is initially mucoid and may
later become mucopurulent because of secondary bacterial infec-
tion. The microbiological causes of acute bronchitis are shown in
Table I. Management should be based on the following princi-
ples:
• assessment of the severity of the symptoms, and colour and
quantity of the sputum
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Antibiotics — to use or not to use, a common question.
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• evaluation for underlying co-mor-
bidity (Table II)
• exclusion of acute bacterial tonsilli-
tis by looking for purulent tonsillar
exudates
• clinical exclusion of pneumonia a
chest radiograph (CXR)
• assessment of the clinical severity
and access to medical care
• informing the patient that the infec-
tion will probably resolve sponta-
neously and about problems associ-
ated with antibiotic over-use and
resistance
• antibiotic allergies.
Crucially, patient satisfaction has been
shown to relate to the quality of the
doctor-patient interaction rather than
the prescription of an antibiotic. The
use of an antibiotic for acute bronchi-
tis is widely discouraged.
If the assessment justifies the adminis-
tration of an antibiotic, either amoxy-
cillin or doxycycline should be pre-
scribed for 5 days. In order to achieve
the concentration of amoxicillin in the
bronchial secretions above the mini-
mum inhibitory concentration (MIC)
(for pneumococcus), the adult dose
should be 500 mg 3 times daily.
Erythromycin can be prescribed with
amoxicillin if there is an outbreak of
mycoplasma or chlamydia infection in
the community. Doxycycline will cover
both the typical respiratory tract
pathogens and the mycoplasma/
chlamydia.  Importantly, treatment for
the ‘atypical’ pathogens should be
continued for 14 days.
ACUTE SINUSITIS
Mucoid nasal discharge with post-
nasal drip and nasal congestion is a
prominent feature of the common cold,
and is not an indication for antibiotic
treatment. Patients should be informed
that these symptoms should resolve
spontaneously within 3 - 4 days.
Persisting symptoms for more than 1
week and a purulent nasal discharge
suggest that acute bacterial sinusitis
has developed. Facial pain, which is
exacerbated by bending forward, or
by direct pressure over the sinuses, is
also highly suggestive of this condi-
tion. 
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Fig. 1. The clinical dilemma of acute bronchitis.
Not giving an antibiotic
• Risk of clinical deterioration
• Perception of poor patient
satisfaction
Giving an antibiotic
• Creating bacterial resistance
• Unnecessary side-effects
• Cost
Table I. Causes of acute bronchitis
Primary infection Secondary infection






Respiratory syncytial virus 
Para-influenza virus
Table II. Conditions associated with increased risk of 
progression to severe lower respiratory tract infection 
Immunocompetent Immunocompromised 
individuals individuals
Persons > 65yrs HIV infection
Chronic cardiovascular disease Leukaemia/lymphoma
Chronic respiratory disease Myeloma
Other chronic medical conditions Other malignancies
Diabetes mellitus Chronic renal failure
Cirrhosis Nephrotic syndrome
Alcoholism Organ transplants





Certain patients develop sinusitis more
readily; the threshold for using an
antibiotic should be lower if the
patient has a history of:
• sinus surgery
• sinus polyps
• bloodstained nasal discharge dur-
ing the current URTI
• mucociliary disorders (rare). 
If acute sinusitis is diagnosed, antibiot-
ic treatment is indicated using amoxi-
cillin (at least 500 mg 3 times daily),
co-amoxiclav (with 500 mg of the




Patients with underlying lung disease
experiencing an infective exacerbation
are more likely to need an antibiotic.
The following points should raise the
suspicion of underlying chronic lung
disease:
• smoking
• daily sputum production for > 3
months yearly for the last 2 years
• gradually increasing effort intoler-
ance  
• previous pulmonary tuberculosis
• history of working underground in
the mines.
Clinical features suggesting chronic
lung disease include:
• prolonged expiration, hyperinflated
chest and wheezing
• fixed coarse inspiratory crackles
(also heard at the mouth) and fin-
ger clubbing.
Symptoms suggesting an infective
exacerbation include increasing
breathlessness, increased volume of
sputum production and more purulent
sputum.  Patients with the following
clinical features should be treated with
an antibiotic:
• severe underlying COPD
• markedly purulent sputum
• evidence of systemic infection
(fever, raised white cell count,
raised erythrocyte sedimentation
rate (ESR) or C-reactive protein
(CRP)
• new infiltrate on chest radiograph
• co-morbidity or an increased risk of
developing pneumonia.
The use of an antibiotic is associated
with the following benefits:
• more rapid improvement in peak
expiratory flow rate
• lower risk of clinical failure and
progression to pneumonia
• two-day reduction in duration of ill-
ness
• lower relapse rate.
An appropriate antibiotic will also
eradicate infections that accelerate
lung destruction and chronic airway
obstruction. Importantly, treatment
should also include inhaled/nebulised
beta2-agonists with ipratropium, pred-
nisone 40 mg daily for 14 days, and
inhaled oxygen if the patient is severe-
ly hypoxaemic. (Note that oxygen sup-
plementation should be used cautious-
ly if hypercarbia is present.) 
The appropriate choice of antibiotic is
detailed in Table III. Intravenous antibi-
otics may be required in severe cases,
but can be ‘switched’ to oral therapy
when clinical improvement occurs.
Moxifloxacin (400 mg daily) and gati-
floxacin (400 mg daily) have excellent
absorption from the gastrointestinal
tract, but are very expensive and
resistance develops rapidly; hence
their use should be restricted to
patients who are allergic to beta-lac-
tam antibiotics. If co-amoxiclav is used
a minimum of 500 mg of the amoxi-
cillin component should be given.
Duration of therapy for severe disease
should be 10 - 14 days.
Prevention
Preventing influenza and severe bacte-
rial infections is a crucial component
of the management of patients with
underlying lung disease. The influenza
vaccine should be given yearly at the
start of the influenza season to all
high-risk patients. The 23 serotype
pneumococcal vaccine (Pneumovax
23 or Imovax Pneumo 23) should also
be given every 5 years to high-risk
patients. The role of the new heptava-
lent pneumococcal vaccine in adults is
still unclear. Long-term physiotherapy
and postural drainage are important
in patients with bronchiectasis.
Clinical example
A 45-year-old woman has bilateral
bronchiectasis diagnosed in child-
hood. Extensive, bilateral lower lobe
disease was seen on a recent high-res-
olution CT scan of the lungs. Her cur-
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Table III. Antibiotic therapy recommended for patients with infective exacerbations of COPD
Condition Patient profile Pathogens Appropriate antibiotic therapy
Simple chronic Younger patient, Streptococcus pneumoniae High-dose amoxicillin or amoxicillin/
bronchitis near normal lung function, Haemophilus influenzae clavulanic acid or macrolide/azalide
few exacerbations Moraxella catarrhalis
Complicated Older patient, impaired As above, but antibiotic Amoxicillin/clavulanic acid, or 2nd 
chronic lung function, frequent resistance more common or 3rd generation cephalosporin,
bronchitis exacerbations > 4/year or new respiratory fluoroquinolone
Bronchiectasis As above, plus continuous As above, plus Gram-nega- Ciprofloxacin or new fluoro-
purulent sputum tive organisms, including   quinolone, or other agent
production, possible Enterobacteriaceae and according to sputum culture
structural damage/ Pseudomonas aeruginosa
bronchiectasis 
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Antibiotic resistance among
the respiratory tract
pathogens is clinically sig-
nificant and increasing rap-
idly, and clinicians treating
outpatients with respiratory
tract infections need to
grapple with the issue of
whether or not an antibiot-
ic should be prescribed.
Acute bronchitis is often
preceded by a viral URTI.
Symptoms progress to
include general malaise,
retrosternal pain, dry ‘tick-
ly’ cough and sputum pro-
duction that is initially
mucoid and may later
become mucopurulent
because of secondary 
bacterial infection.
Crucially, patient satisfac-
tion has been shown to
relate to the quality of the
doctor-patient interaction
rather than the prescription
of an antibiotic. The use of
an antibiotic for acute
bronchitis is widely 
discouraged.
rent effort tolerance is good and she
describes grade 2 exertional dysp-
noea. Over the years she has had
many courses of antibiotics as an out-
patient and inpatient, and a recent
sputum culture grew Pseudomonas
aeruginosa resistant to amoxicillin, co-
trimoxazole, doxycycline, co-amoxi-




This patient has been colonised by
pseudomonas resistant to multiple
antibiotics. This organism would have
acquired the antibiotic resistance
genes (which it does with notorious
ease) during previous courses of treat-
ment. During this patient’s next infec-
tive exacerbation another sputum cul-
ture will have to be taken and an
urgent Gram stain done. If the stain
does not clearly show another organ-
ism (e.g. Gram-positive pneumococ-
cus) the clinician will have to presume
that the infecting organism is the
pseudomonas and treat accordingly. 
Outpatient treatment can be given
with ofloxacin, but both the clinician
and the patient need to understand
that in time the organism will become
resistant to this drug. Inpatient treat-
ment should be with intravenous ceftri-
axone and gentamicin: both are given
in an attempt to prevent the organism
acquiring resistance to these valuable
drugs. The amikacin and piptazobac-
tam can be kept in reserve. 
‘Surveillance’ sputum culture and sen-
sitivity testing should be done twice
yearly. Treatment should also include
chest physiotherapy and appropriate
vaccination. The ultimate goal of treat-
ment is to slow the progression of the
bronchiectasis and to preserve as
much healthy lung tissue as possible.
Reference available on request.
Antibiotic over-prescribing for acute
upper respiratory tract infections
(URTIs) is common and promotes
antibiotic resistance.
In patients without underlying co-
morbidity the majority of URTIs will
resolve spontaneously. Patient satis-
faction is related to the quality of
the doctor-patient interaction rather
than to receiving an antibiotic pre-
scription.
Mucoid sputum or nasal discharge
in itself is not an indication for an
antibiotic.
Acute bacterial sinusitis can be
diagnosed 7 - 10 days after an
URTI, when nasal discharge
becomes purulent and congestion
persists, and is associated with
facial pain worsened by bending
forward. A history of sinus surgery
or nasal polyps suggests that the
patient may develop sinusitis more
readily, especially if the discharge
is bloodstained.
Patients with acute bronchitis and
severe underlying lung disease or
co-morbidity may benefit from
being treated early with an antibiot-
ic to prevent pneumonia or to limit
ongoing lung damage.
Sputum culture and sensitivity test-
ing allow rational antibiotic selec-
tion for patients with structural lung
disease (chronic bronchitis, emphy-
sema and bronchiectasis) and
recurrent respiratory tract infec-
tions.
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